The Latin America, Middle East and Africa Aptamers Market would witness market growth of 21.3% CAGR during the forecast period (2021-2027).
Aptamers have a high level of stability. Proteins are easily denatured and lose their tertiary structure at high temperatures, whereas oligonucleotides are more thermally robust and preserve their structures over multiple denaturation/renaturation cycles.
As a result, the most significant benefit of oligonucleotide-based aptamers over protein-based antibodies is their temperature stability. After re-annealing, aptamers regain their natural shape and can bind to targets, whereas antibodies are easily irreversibly denatured. As a result, aptamers can be utilized in a variety of assays.
Aptamers may be easily changed using a variety of chemical processes to improve their stability and resistance to nucleases. Additionally, signal moieties like fluorophores and quenchers can be used to considerably simplify the manufacturing of biosensors.
The growth of the market over Latin America, the Middle East, and Africa are expected to remain constant. In market clinical tests, these aptamers failed to fulfill the needs of safeguarded and efficient criteria. Aptamers have properties that allow them to identify virus-infected cells or viruses, making them a viable alternative to monoclonal antibodies. A variety of aptamers can be employed to disrupt each stage of the viral replication cycle, as well as to prevent viral entry into cells.
The Brazil market dominated the LAMEA Aptamers Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $5.7 million by 2027. The Argentina market would experience a CAGR of 22% during (2021 - 2027). Additionally, The UAE market is poised to grow a CAGR of 21% during (2021 - 2027).
Based on Type, the market is segmented into DNA Aptamers, XNA Aptamers and RNA Aptamers. Based on Application, the market is segmented into Therapeutics Development, Research & Development, Diagnostic and Others. Based on Technology, the market is segmented into SELEX and Others. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Kaneka Corporation, Aptamer Group PLC, SomaLogic, Inc., RayBiotech Life, Inc., Neoventures Biotechnology, Inc., Maravai Lifesciences Holdings, Inc., Aptus Biotech, Base Pair Biotechnologies, Inc., Alpha Diagnostic International, Inc., and Vivonics, Inc.
Scope of the Study
Market Segments covered in the Report:
• DNA Aptamers
• XNA Aptamers and
• RNA Aptamers
• Therapeutics Development
• Research & Development
• Diagnostic and
• SELEX and
By End User
• Pharmaceutical & Biotechnology Companies
• Academic & Government Research Institutes
• CROs and
• Saudi Arabia
• South Africa
• Rest of LAMEA
• Kaneka Corporation
• Aptamer Group PLC
• SomaLogic, Inc.
• RayBiotech Life, Inc.
• Neoventures Biotechnology, Inc.
• Maravai Lifesciences Holdings, Inc.
• Aptus Biotech
• Base Pair Biotechnologies, Inc.
• Alpha Diagnostic International, Inc.
• Vivonics, Inc.
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free